INC snags Phase II-IV ops in $50M deal

Canada's MDS has sold off its Phase II-IV clinical development ops to INC Research for $50 million. And with the focus at MDS shifting to early-stage research, executives say they have also put their central labs operation on the market.  

INC's deal for the Phase II-IV CRO business includes 800 employees working in 25 countries. "This acquisition reinforces our long-standing commitment... to continuously improve service in areas most important to our customers--therapeutic expertise, talent and experience, and a broader geographic footprint," said INC CEO Jim Ogle.

"While our investments in MDS Pharma Services' Late Stage have significantly strengthened the business, further success requires greater scale," said MDS chief Stephen DeFalco. "By divesting our Phase II-IV operations, we will be better able to take advantage of our core competencies in Early Stage."

- check out the press release
- read the report from the Canadian Press

Suggested Articles

Omega Therapeutics is working on treatments that adjust gene expression up or down without making permanent changes to the genome.

The IPO window is still wide open for biotech, and French Big Pharma-partnered Innate is looking to jump right on through.

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.